Compare AUPH & NUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUPH | NUV |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2014 | N/A |
| Metric | AUPH | NUV |
|---|---|---|
| Price | $14.25 | $8.87 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 448.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.96% |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $16.53 | N/A |
| Revenue Next Year | $16.24 | N/A |
| P/E Ratio | $7.06 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $6.83 | $8.38 |
| 52 Week High | $16.54 | $9.26 |
| Indicator | AUPH | NUV |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 25.12 |
| Support Level | $13.52 | $8.48 |
| Resistance Level | $15.23 | $9.11 |
| Average True Range (ATR) | 0.45 | 0.06 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 36.73 | 2.44 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.